Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
ibi362 save search
Innovent Announces Primary Endpoint Met in the Second Phase 2 Clinical Trial of IBI302 (anti-VEGF/complement) in Treating Neovascular Age-related Macular Degeneration (nAMD)
Published: 2024-03-19 (Crawled : 00:00) - prnewswire.com
SNYNF | $92.966 0.07% -2.18% 630
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
SNY | $46.24 0.68% 0.63% 1.6M
|
Health Technology
|
| O: -1.51%
H: 0.0%
C: 0.0%
ibi302 macular trial
Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity
Published: 2024-01-02 (Crawled : 00:00) - prnewswire.com
SNYNF | $92.966 0.07% -2.18% 630
|
Health Technology
|
| O: -0.02%
H: 0.41%
C: 0.41%
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: -0.43%
H: 2.12%
C: 2.03%
SNY | $46.24 0.68% 0.63% 1.6M
|
Health Technology
|
| O: -0.45%
H: 0.0%
C: 0.0%
INCY | $53.43 -0.78% -0.8% 1.6M
|
Health Technology
|
| O: -0.64%
H: 4.97%
C: 4.9%
ibi362 obesity first chinese study
Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications
Published: 2023-12-18 (Crawled : 00:00) - prnewswire.com
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: 1.61%
H: 1.14%
C: 0.57%
SNY | $46.24 0.68% 0.63% 1.6M
|
Health Technology
|
| O: 1.25%
H: 0.0%
C: 0.0%
INCY | $53.43 -0.78% -0.8% 1.6M
|
Health Technology
|
| O: -0.03%
H: 0.06%
C: -2.67%
ibi362 obesity publication communications chinese results
Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Type 2 Diabetes in Diabetes Care
Published: 2023-11-22 (Crawled : 05:00) - prnewswire.com
SNYNF | $92.966 0.07% -2.18% 630
|
Health Technology
|
| O: -0.74%
H: 0.71%
C: 0.71%
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: -0.44%
H: 0.63%
C: -0.05%
SNY | $46.24 0.68% 0.63% 1.6M
|
Health Technology
|
| O: -0.34%
H: 0.0%
C: 0.0%
ibi362 publication care chinese diabetes results phase 2
Innovent Presents Clinical Data of Two Ophthalmic Bispecific Antibodies IBI302 (anti-VEGF/complement) and IBI324 (anti-VEGF-A/Ang-2) at American Academy of Ophthalmology (AAO) Annual Meeting 2023
Published: 2023-11-06 (Crawled : 00:00) - prnewswire.com
SNYNF | $92.966 0.07% -2.18% 630
|
Health Technology
|
| O: 0.16%
H: 0.0%
C: 0.0%
SNY | $46.24 0.68% 0.63% 1.6M
|
Health Technology
|
| O: 0.21%
H: 0.0%
C: 0.0%
ibi302 ibi324 meeting
Innovent Announces Robust Weight Loss Efficacy, Multiple Metabolic Benefits and Favorable Safety Profile of Higher Dose 9 mg Mazdutide (IBI362) after 48-week Treatment in Phase 2 Study for Obesity
Published: 2023-10-30 (Crawled : 00:00) - prnewswire.com
SNYNF | $92.966 0.07% -2.18% 630
|
Health Technology
|
| O: 2.76%
H: 0.0%
C: 0.0%
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: 0.69%
H: 0.0%
C: 0.0%
SNY | $46.24 0.68% 0.63% 1.6M
|
Health Technology
|
| O: -0.85%
H: 0.0%
C: 0.0%
ibi362 obesity metabolic favorable treatment study benefits
Innovent Announces First Patient Dosed in the Phase 3 Clinical Study (STAR) of Efdamrofusp Alfa (IBI302), a First-in-class Ophthalmic Anti-VEGF and Anti-Complement Bispecific Fusion Protein for the Treatment of Neovascular Age-related Macular Degeneration
Published: 2023-10-09 (Crawled : 00:00) - prnewswire.com
SNY | $46.24 0.68% 0.63% 1.6M
|
Health Technology
|
| O: 0.19%
H: 0.0%
C: 0.0%
INCY | $53.43 -0.78% -0.8% 1.6M
|
Health Technology
|
| O: -0.77%
H: 0.21%
C: -0.37%
ibi302 macular treatment protein study
Innovent Announces Phase 2 Clinical Study of Higher dose 9 mg Mazdutide (IBI362) in Chinese Adults with Obesity Achieved the 24-Week Primary Endpoint
Published: 2023-05-11 (Crawled : 01:00) - prnewswire.com
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: 0.18%
H: 0.03%
C: -0.26%
SNY | $46.24 0.68% 0.63% 1.6M
|
Health Technology
|
| O: -0.28%
H: 0.0%
C: 0.0%
INCY | $53.43 -0.78% -0.8% 1.6M
|
Health Technology
|
| O: 0.3%
H: 0.12%
C: 0.09%
ibi362 obesity chinese study
Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (DREAMS-2) of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes
Published: 2023-01-10 (Crawled : 19:00) - biospace.com/
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: -0.24%
H: 1.21%
C: 1.07%
SNY | $46.24 0.68% 0.63% 1.6M
|
Health Technology
|
| O: -0.49%
H: 0.0%
C: 0.0%
INCY | $53.43 -0.78% -0.8% 1.6M
|
Health Technology
|
| O: 0.1%
H: 2.05%
C: 0.82%
ibi362 chinese diabetes study
Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (DREAMS-1) of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes
Published: 2023-01-09 (Crawled : 17:00) - biospace.com/
SNYNF | $92.966 0.07% -2.18% 630
|
Health Technology
|
| O: 1.38%
H: 0.28%
C: 0.28%
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: 0.29%
H: 0.27%
C: -3.89%
SNY | $46.24 0.68% 0.63% 1.6M
|
Health Technology
|
| O: 1.82%
H: 0.0%
C: 0.0%
INCY | $53.43 -0.78% -0.8% 1.6M
|
Health Technology
|
| O: 0.02%
H: 0.36%
C: -2.56%
ibi362 chinese diabetes study
Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (GLORY-1) of Mazdutide (IBI362) in Chinese Adults with Overweight or Obesity
Published: 2022-11-15 (Crawled : 01:00) - prnewswire.com
SNYNF | $92.966 0.07% -2.18% 630
|
Health Technology
|
| O: -0.27%
H: 0.0%
C: 0.0%
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: 0.25%
H: 0.01%
C: -1.96%
SNY | $46.24 0.68% 0.63% 1.6M
|
Health Technology
|
| O: 1.37%
H: 0.0%
C: 0.0%
INCY | $53.43 -0.78% -0.8% 1.6M
|
Health Technology
|
| O: 1.27%
H: 0.0%
C: -1.86%
ibi362 obesity chinese study
Innovent Announces Phase Ib Results of Higher-dose Mazdutide (IBI362) in Chinese Participants with Overweight or Obesity Published in eClinicalMedicine
Published: 2022-10-17 (Crawled : 01:00) - prnewswire.com
SNYNF | $92.966 0.07% -2.18% 630
|
Health Technology
|
| O: 0.67%
H: 0.0%
C: 0.0%
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: 0.42%
H: 1.44%
C: -0.01%
SNY | $46.24 0.68% 0.63% 1.6M
|
Health Technology
|
| O: 0.51%
H: 0.95%
C: 0.65%
INCY | $53.43 -0.78% -0.8% 1.6M
|
Health Technology
|
| O: 0.9%
H: 1.42%
C: 0.92%
ibi362 obesity chinese results
Significant Glycemic Control and Weight Loss: Innovent Announces Phase 2 Study of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes Met Primary Endpoint
Published: 2022-07-19 (Crawled : 01:00) - prnewswire.com
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: 0.72%
H: 1.02%
C: 0.65%
INCY | $53.43 -0.78% -0.8% 1.6M
|
Health Technology
|
| O: -0.83%
H: 0.0%
C: 0.0%
ibi362 chinese control diabetes study phase 2
Innovent Announces Phase 1b Study Results of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes Published in Nature Communications
Published: 2022-06-28 (Crawled : 01:00) - biospace.com/
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: 0.99%
H: 0.0%
C: 0.0%
INCY | $53.43 -0.78% -0.8% 1.6M
|
Health Technology
|
| O: -0.08%
H: 0.0%
C: 0.0%
ibi362 communications chinese diabetes results phase 2b
Innovent Announces Phase 1b Study Results of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes Published in Nature Communications
Published: 2022-06-29 (Crawled : 01:00) - prnewswire.com
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: -2.65%
H: 2.06%
C: 1.52%
INCY | $53.43 -0.78% -0.8% 1.6M
|
Health Technology
|
| O: -2.07%
H: 0.58%
C: 0.25%
ibi362 communications chinese diabetes results phase 2b
Innovent Releases Results of High-dose Cohorts in Phase 1 Clinical Study of Mazdutide (IBI362) in Chinese Adults with Overweight or Obesity at ENDO 2022
Published: 2022-06-13 (Crawled : 01:00) - prnewswire.com
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: -3.12%
H: 0.0%
C: 0.0%
INCY | $53.43 -0.78% -0.8% 1.6M
|
Health Technology
|
| O: -3.69%
H: 0.0%
C: 0.0%
ibi362 obesity chinese results phase 1
Innovent Announces Phase 2 study of Mazdutide（IBI362） in Chinese Participants with Overweight or Obesity Met Primary and All Key Secondary Endpoints
Published: 2022-06-08 (Crawled : 01:00) - prnewswire.com
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: 3.02%
H: 0.98%
C: 0.34%
INCY | $53.43 -0.78% -0.8% 1.6M
|
Health Technology
|
| O: 1.5%
H: 1.13%
C: -0.01%
ibi362 obesity chinese phase 2
Innovent Releases Results of a Phase 1 Clinical Study of IBI362, a Dual Glucagon-like Peptide-1 and Glucagon Receptor Agonist in Chinese Patients with Type 2 Diabetes at the International Diabetes Federation Congress 2021
Published: 2021-12-07 (Crawled : 01:00) - prnewswire.com
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: -0.84%
H: 0.49%
C: 0.36%
INCY | $53.43 -0.78% -0.8% 1.6M
|
Health Technology
|
| O: -1.43%
H: 3.35%
C: 2.19%
chinese diabetes phase 1 results
Innovent Announces the Results of the Phase Ib Clinical Trial of IBI302, a First-in-class Anti-VEGF and Anti-Complement Bi-specific Fusion Protein for Neovascular Age-Related Macular Degeneration at 2021 American Academy of Ophthalmology
Published: 2021-11-15 (Crawled : 01:00) - prnewswire.com
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: -0.9%
H: 0.08%
C: -0.37%
INCY | $53.43 -0.78% -0.8% 1.6M
|
Health Technology
|
| O: 1.35%
H: 0.0%
C: -1.12%
results trial macular
Innovent Announces First Patient with Type 2 Diabetes Dosed in a Phase 2 Clinical Trial of IBI362 (a GLP-1R and Glucagon Receptor Dual Agonist) in China
Published: 2021-09-08 (Crawled : 00:00) - prnewswire.com
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: -0.08%
H: 0.44%
C: 0.09%
diabetes phase 2 china trial
Gainers vs Losers
| 45% | 55% |
Top 10 Gainers
KAVL | $6.3 135.96% 57.45% 44M
|
Wholesale Trade
PXMD | $0.74 79.7% 44.16% 4.5M
|
Health Technology
DYNT | $0.3704 -5.27% 43.09% 5.5M
|
Health Technology
LGVN P 3 d | $2.93 73.37% 42.52% 56M
|
HUBC | $1.95 50.0% 32.99% 73M
|
n/a
SPCB | $0.4004 45.07% 31.75% 130M
|
Electronic Technology
ONVO | $1.35 33.65% 24.62% 53M
|
Health Technology
OMQS | $0.7038 35.35% 24.3% 3.5M
|
Professional, Scientific, and T...
SNPO | $10.54 29.48% 22.88% 3.9M
|
EEIQ | $1.16 27.46% 20.86% 6.9K
|
Educational Services
Your saved searches
Save your searches and get alerts when important news are released.